Patients in this study will receive both medications over a period of up to 24 months. The study will measure how many patients have their tumors shrink or disappear completely after receiving this treatment combination. Doctors will use imaging scans to check the size of the tumors and determine whether the treatment is working. The study will also track how long patients live, how long the cancer stays under control without getting worse, and how long any positive response to the treatment lasts. Additionally, the study will monitor how long patients can maintain a response where their cancer is either shrinking, disappearing, or staying stable.

Throughout the study, doctors will carefully watch for any side effects or unwanted reactions that patients may experience from the medications. The severity of these side effects will be recorded and graded according to a standard system used in cancer research. The study will also ask patients questions about their quality of life to understand how the treatment affects their daily activities and overall well-being. Patients will need to have tumor tissue samples available for testing, and they must have measurable disease that can be tracked on scans. The study requires patients to be healthy enough to participate, with adequate blood cell counts, liver function, and kidney function.

The purpose of this study is to evaluate how well avelumab works in maintaining the health of patients who have already received initial chemotherapy that includes a drug called cisplatin. Patients participating in the study will receive avelumab after their first round of chemotherapy if their cancer has not worsened. The study will monitor patients over a period to see how long they remain free from cancer progression and to assess their overall survival.

Throughout the study, researchers will also look at the safety of avelumab by observing any side effects that occur. Additionally, the study will evaluate the quality of life of patients using questionnaires. The trial aims to provide valuable information on the effectiveness and safety of avelumab as a maintenance treatment for this type of cancer.

The treatment involves receiving pembrolizumab as an infusion at a dose of up to 200 mg, along with vorinostat capsules at a dose of up to 400 mg daily. The treatment period may continue for up to 105 weeks. During the study, doctors will monitor how the cancer responds to the treatment combination through regular medical examinations and imaging tests.

Both medications work differently to fight cancer. Pembrolizumab is an immunotherapy drug that helps the body’s immune system recognize and attack cancer cells. Vorinostat belongs to a group of medications that work by affecting how genes behave in cancer cells. This combination approach aims to provide better results than using either medication alone.